LCTX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.96M

-31.67%

-0.047

+371.4%

1.77M

+18.12%

-0.022

+10%

6.57M

+137.76%

-0.010

-92.31%

Estimates Revision

The market is revising Upward the revenue expectations for Lineage Cell Therapeutics, Inc. (LCTX) for FY2025, with the revenue forecasts being adjusted by 10.57% over the past three months. During the same period, the stock price has changed by -2.29%.

Revenue Estimates for FY2025

Revise Upward

+10.57%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+57.04%

In Past 3 Month

Stock Price

Go Down

-2.29%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast LCTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LCTX is 5.00 USD with a low forecast of 3.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

3.00

Averages

5.00

High

9.00

Current: 0.000

Low

3.00

Averages

5.00

High

9.00

H.C. Wainwright

Buy

maintain

2025-11-24

Reason

H.C. Wainwright

Price Target

2025-11-24

maintain

Buy

Reason

H.C. Wainwright reiterated a Buy rating and $9 price target on Lineage Cell Therapeutics (LCTX), saying the major breakout event the firm is looking for is visibility out of global partner Roche (RHHBY) regarding OpRegen data and next steps. Monday's $5M milestone represents yet another tangible piece of evidence for Roche's progress in the OpRegen program for which they have global rights for dry-AMD and geographic atrophy, the analyst tells investors in a research note. The firm added that data, anecdotes, and comps provide significant support that OpRegen is moving into later studies in Roche's hands.

B. Riley Securities

Mayank Mamtani

Strong Buy

Maintains

$4 → $3

2025-03-14

Reason

B. Riley Securities

Mayank Mamtani

Price Target

$4 → $3

2025-03-14

Maintains

Strong Buy

Reason

B. Riley analyst Mayank Mamtani lowered the firm's price target on Lineage Cell Therapeutics (LCTX) to $3 from $4 and keeps a Buy rating on the shares. Lineage Cell Therapeutics' Q4 recap focused on Roche (RHHBY)-partnered OpRegen program, steadily advancing earlier-stage wholly-owned programs, and Lineage's dominant position in large-scale allogeneic manufacturing to produce millions of retinal pigment epithelium cells, the analyst tells investors in a research note. The OpRegen dry AMD opportunity could come through the ongoing Phase II GAlette study interim data release, and Roche opting to progress to a randomized controlled study to confirm high efficacy benefits noted with optimized delivery system in sizeable patient population, the firm says.

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2025-03-11

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2025-03-11

Reiterates

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

2025-03-11

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-03-11

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$3 → $2

2025-02-11

Reason

D. Boral Capital

Jason Kolbert

Price Target

$3 → $2

2025-02-11

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2025-01-31

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2025-01-31

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Lineage Cell Therapeutics Inc (LCTX.A) is -16.22, compared to its 5-year average forward P/E of -9.84. For a more detailed relative valuation and DCF analysis to assess Lineage Cell Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.84

Current PE

-16.22

Overvalued PE

-5.80

Undervalued PE

-13.89

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-13.90

Current EV/EBITDA

-13.75

Overvalued EV/EBITDA

12.16

Undervalued EV/EBITDA

-39.97

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

41.99

Current PS

30.61

Overvalued PS

91.92

Undervalued PS

-7.95

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

LCTX News & Events

Events Timeline

No data

News

3.5

2025-12-16Newsfilter

Avant Technologies Drives 67.5% Market Share in Cell Therapy Manufacturing

2.0

2025-12-04Benzinga

Snowflake, Symbotic, and Other Major Stocks Decline in Thursday's Pre-Market Trading

1.0

2025-09-13Newsfilter

Lineage Cell Therapeutics, Inc. (LCTX) Shares Prepared Remarks at H.C. Wainwright's 27th Annual Global Investment Conference

People Also Watch

Frequently Asked Questions

What is Lineage Cell Therapeutics Inc (LCTX) stock price today?

The current price of LCTX is 1.71 USD — it has decreased -2.84 % in the last trading day.

What is Lineage Cell Therapeutics Inc (LCTX)'s business?

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological and ophthalmic conditions. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, it designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.

What is the price predicton of LCTX Stock?

What is Lineage Cell Therapeutics Inc (LCTX)'s revenue for the last quarter?

Lineage Cell Therapeutics Inc revenue for the last quarter amounts to 3.68M USD, decreased -2.59 % YoY.

What is Lineage Cell Therapeutics Inc (LCTX)'s earnings per share (EPS) for the last quarter?

Lineage Cell Therapeutics Inc. EPS for the last quarter amounts to -0.13 USD, increased 550.00 % YoY.

What changes have occurred in the market's expectations for Lineage Cell Therapeutics Inc (LCTX)'s fundamentals?

How many employees does Lineage Cell Therapeutics Inc (LCTX). have?

Lineage Cell Therapeutics Inc (LCTX) has 70 emplpoyees as of January 10 2026.

What is Lineage Cell Therapeutics Inc (LCTX) market cap?

Today LCTX has the market capitalization of 393.86M USD.